The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) presents an important clinical challenge, as it does not respond to endocrine therapies or other available targeting agents. FOXM1, an oncogenic transcriptional factor, has reported to be upregulated and associated with poor clinical outcomes in TNBC patients. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulhaka, Karan, Kanokwiroon, Kanyanatt, Khongkow, Mattaka, Bissanum, Rassanee, Khunpitak, Thanaporn, Khongkow, Pasarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269391/
https://www.ncbi.nlm.nih.gov/pubmed/34206484
http://dx.doi.org/10.3390/ijms22136685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269391/
https://www.ncbi.nlm.nih.gov/pubmed/34206484
http://dx.doi.org/10.3390/ijms22136685

Ejemplares similares